Participants will receive oral tablets of upadacitinib or matching placebo once daily for 52 weeks in Study 1 and Study 2. Eligible participants from Study 1 and Study 2 will receive oral tablets of upadacitinib once daily for 52 weeks in Study 3.

Who can Participate

Clinical diagnosis of SLE at least 24 weeks prior to study screening. On stable background treatment of more than 60 days prior to baseline visit. Class III/IV Lupus Nephritis that was treated with induction therapy within the 6 months prior to screening is an exclusion. SLE overlap syndromes including rheumatoid arthritis, systemic sclerosis, polymyositis, dermatomyositis, or mixed connective tissue disease is an exclusion. Inclusion Criteria: Clinical diagnosis of systemic lupus erythematosus (SLE) at least 24 weeks prior to screening as defined by the 2019 European Alliance of Associations for Rheumatology (EULAR)/ American College of Rheumatology (ACR) classification criteria for SLE. At Screening, must have at least one of the following: antinuclear antibody (ANA) positive (titer >= 1:80) anti-double stranded deoxyribonucleic acid (dsDNA) positive anti-Smith positive Hybrid systemic lupus erythematosus disease activity index (hSLEDAI) >= 6, of which >= 4 points are clinical (not based on laboratory criteria), independently reviewed by the MCDR at Screening. Clinical hSLEDAI score (not based on laboratory criteria) must be re-confirmed as >= 4 at the Baseline visit. Lupus headache or organic brain syndrome do not count towards the hSLEDAI points required for eligibility but should be documented on the hSLEDAI if present. Physician's Global Assessment (PhGA) >= 1 during screening period. On stable background treatment for >= 60 days prior to Baseline (with the exception of oral corticosteroid [OCS], which must be at a stable dose for >=14 days prior to Baseline) with antimalarial(s) [hydroxychloroquine <= 400 mg daily, chloroquine <= 500 mg daily, quinacrine <= 100 mg daily]; and/or prednisone (or prednisone-equivalent) (<= 20 mg daily); and/or no more than 1 of the following: azathioprine (<= 150 mg daily), 6-mercaptopurine (<= 150 mg daily), mycophenolate mofetil (<= 2 g daily), mycophenolate sodium <= 1,440 mg/day, leflunomide (<= 20 mg daily), cyclosporine, tacrolimus, voclosporin (<= 23.7 mg twice daily), methotrexate (<= 25 mg weekly), or mizoribine (<= 150 mg daily). Exclusion Criteria: Class III/IV lupus nephritis that was treated with induction therapy within the 6 months prior to Screening. Active neuropsychiatric SLE (excluding lupus headache) within the 6 months prior to Screening. SLE overlap syndromes including, but not limited to, rheumatoid arthritis, systemic sclerosis, polymyositis, dermatomyositis, or mixed connective tissue disease (Sjögren's syndrome is permitted). Antiphospholipid syndrome and prior unprovoked venous or arterial thrombosis who are not on stable and adequate anticoagulation. Two or more episodes of herpes zoster, or one or more episodes of disseminated herpes zoster or herpes zoster ophthalmicus. History of malignancy, except for successfully treated non-melanoma skin cancer or localized carcinoma in situ of the cervix. Pregnancy, breastfeeding, or considering becoming pregnant during the study. Clinically relevant or significant ECG abnormalities at Screening. Planned elective surgery that would impact study procedures or assessments through the completion of the Week 52 assessments. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Study ID

More information available at ClinicalTrials.gov: NCT05843643